Pericleous Charis, Ripoll Vera M, Giles Ian, Ioannou Yiannis
Centre for Rheumatology, University College London, London, UK.
Methods Mol Biol. 2014;1134:221-35. doi: 10.1007/978-1-4939-0326-9_17.
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent vascular thrombosis (VT) and/or pregnancy morbidity (PM) in the presence of persistent antiphospholipid antibodies (aPL), detected by lupus anticoagulant (LA), anticardiolipin (aCL) antibody, and/or anti-β₂ glycoprotein I (aβ₂GPI) antibody assays. These aPL, considered to be diagnostic markers and pathogenic drivers of APS, are a heterogeneous group of antibodies directed against anionic phospholipids, phospholipid-binding plasma proteins, and phospholipid-protein complexes. Although APS is currently considered as a single disease, it presents with a wide range of clinical symptoms and biological characteristics. The clinical diagnosis of APS in a patient with symptoms and signs is dependent upon the presence of a persistently positive result in an aPL assay. The tests recommended for detecting aPL are the standardized enzyme-linked immunosorbent assay (ELISA) to detect aCL and aβ₂GPI and clotting assays for LA performed according to the guidelines of the International Society on Thrombosis and Haemostasis. This chapter describes the standard laboratory test for the diagnosis of APS discussing the clinical and theoretical aspects of LA, aCL, and aβ₂GPI assays.
抗磷脂综合征(APS)是一种自身免疫性疾病,其特征为在存在通过狼疮抗凝物(LA)、抗心磷脂(aCL)抗体和/或抗β₂糖蛋白I(aβ₂GPI)抗体检测出的持续性抗磷脂抗体(aPL)时,反复出现血管血栓形成(VT)和/或妊娠并发症(PM)。这些aPL被认为是APS的诊断标志物和致病驱动因素,是一组针对阴离子磷脂、磷脂结合血浆蛋白和磷脂 - 蛋白复合物的异质性抗体。尽管APS目前被视为一种单一疾病,但其临床表现出广泛的临床症状和生物学特征。对于有症状和体征的患者,APS的临床诊断取决于aPL检测结果持续呈阳性。推荐用于检测aPL的试验是根据国际血栓与止血学会指南进行的标准化酶联免疫吸附测定(ELISA)以检测aCL和aβ₂GPI,以及用于LA的凝血试验。本章描述了用于诊断APS的标准实验室检测,讨论了LA、aCL和aβ₂GPI检测的临床和理论方面。